Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High – Time to Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $27.80 and last traded at $27.45, with a volume of 139198 shares trading hands. The stock had previously closed at $27.53.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ELVN shares. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Robert W. Baird assumed coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target on the stock. Finally, Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th.

Enliven Therapeutics Stock Up 0.7 %

The company has a 50 day simple moving average of $23.26 and a 200-day simple moving average of $22.15. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -14.62 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 2,825 shares of the business’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $77,715.75. Following the completion of the sale, the director now directly owns 125,760 shares of the company’s stock, valued at $3,459,657.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Enliven Therapeutics news, COO Anish Patel sold 17,475 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $25.07, for a total transaction of $438,098.25. Following the transaction, the chief operating officer now owns 376,552 shares of the company’s stock, valued at $9,440,158.64. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard A. Heyman sold 2,825 shares of the business’s stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $27.51, for a total value of $77,715.75. Following the completion of the transaction, the director now owns 125,760 shares in the company, valued at $3,459,657.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 166,854 shares of company stock valued at $4,255,626 over the last three months. Corporate insiders own 29.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. First Turn Management LLC purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth about $9,657,000. Janus Henderson Group PLC increased its stake in shares of Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $4,489,000. Baker BROS. Advisors LP purchased a new position in Enliven Therapeutics in the first quarter valued at approximately $2,020,000. Finally, Nicholas Investment Partners LP purchased a new stake in Enliven Therapeutics in the second quarter worth $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.